Michaela Liedtke
About
Michaela Liedtke is a scholar working on Molecular Biology, Hematology and Oncology.
According to data from OpenAlex, Michaela Liedtke has authored 167 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Molecular Biology, 84 papers in Hematology and 58 papers in Oncology. Recurrent topics in Michaela Liedtke's work include Amyloidosis: Diagnosis, Treatment, Outcomes (57 papers), Multiple Myeloma Research and Treatments (51 papers) and Acute Lymphoblastic Leukemia research (40 papers). Michaela Liedtke is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (57 papers), Multiple Myeloma Research and Treatments (51 papers) and Acute Lymphoblastic Leukemia research (40 papers). Michaela Liedtke collaborates with scholars based in United States, Germany and Italy. Michaela Liedtke's co-authors include Ronald Witteles, Anjali S. Advani, Daniel J. DeAngelo, Wendy Stock, Erik Vandendries, Hagop M. Kantarjian, Matthias Stelljes, Nicola Gökbuget, Susan O’Brien and Barbara Sleight and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.
In The Last Decade
Michaela Liedtke
159 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michaela Liedtke United States | 36 | 2.5k | 2.1k | 1.7k | 1.2k | 624 | 167 | 5.0k | ||
| Lia Gore United States | 43 | 2.6k 1.0× | 2.6k 1.2× | 1.1k 0.6× | 1.1k 1.0× | 673 1.1× | 202 | 6.1k | ||
| Josef Vormoor Germany | 35 | 3.2k 1.3× | 3.5k 1.6× | 2.7k 1.6× | 1.2k 1.0× | 938 1.5× | 117 | 7.8k | ||
| Keith Stockerl‐Goldstein United States | 36 | 1.7k 0.7× | 1.8k 0.9× | 3.3k 1.9× | 447 0.4× | 671 1.1× | 200 | 5.2k | ||
| Pamela S. Becker United States | 39 | 2.4k 1.0× | 1.5k 0.7× | 3.7k 2.1× | 658 0.6× | 1.3k 2.0× | 221 | 6.0k | ||
| David A. Rizzieri United States | 44 | 3.0k 1.2× | 2.5k 1.2× | 4.3k 2.5× | 990 0.8× | 1.6k 2.5× | 309 | 8.1k | ||
| Benjamin Esterni France | 32 | 1.4k 0.6× | 2.2k 1.0× | 1.0k 0.6× | 297 0.3× | 422 0.7× | 75 | 4.4k | ||
| Albrecht Reichle Germany | 27 | 1.0k 0.4× | 1.8k 0.8× | 1.4k 0.8× | 1.5k 1.3× | 429 0.7× | 125 | 3.8k | ||
| Tibor Kovacsovics United States | 29 | 1.4k 0.5× | 880 0.4× | 2.3k 1.4× | 1.1k 0.9× | 639 1.0× | 123 | 3.7k | ||
| Hetty E. Carraway United States | 35 | 1.7k 0.7× | 1.1k 0.5× | 1.4k 0.8× | 275 0.2× | 815 1.3× | 212 | 3.6k | ||
| Muzaffar H. Qazilbash United States | 34 | 1.2k 0.5× | 1.4k 0.7× | 2.7k 1.6× | 523 0.4× | 508 0.8× | 312 | 3.9k |
Countries citing papers authored by Michaela Liedtke
Since
Specialization
Citations
This map shows the geographic impact of Michaela Liedtke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela Liedtke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela Liedtke more than expected).
Fields of papers citing papers by Michaela Liedtke
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michaela Liedtke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela Liedtke. The network helps show where Michaela Liedtke may publish in the future.
Co-authorship network of co-authors of Michaela Liedtke
This figure shows the co-authorship network connecting the top 25 collaborators of Michaela Liedtke. A scholar is included among the top collaborators of Michaela Liedtke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaela Liedtke. Michaela Liedtke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hosoya, Hitomi, Brian J. Sworder, Bita Sahaf, et al.. (2025). Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma. Nature Communications. 16(1). 1824–1824.
2.
Quach, Hang, Bradley Augustson, Hanlon Sia, et al.. (2024). First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1026–1026.
3.
Gertz, Morie A., Adam D. Cohen, Raymond L. Comenzo, et al.. (2023). P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES. HemaSphere. 7(S2). 41–42.
4.
Rosenbaum, Cara A., Michaela Liedtke, Paul J. Christos, et al.. (2023). Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab. Blood. 142(Supplement 1). 3402–3402.
5.
Miao, Yu Rebecca, Kaushik N. Thakkar, Can Cenik, et al.. (2022). Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. The Journal of Experimental Medicine. 219(9).
6.
Matsumiya, Wataru, Irmak Karaca, Muhammad Hassan, et al.. (2021). Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. American Journal of Ophthalmology Case Reports. 23. 101133–101133.
7.
Gökbuget, Nicola, Anjali S. Advani, Matthias Stelljes, et al.. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research. 88. 106283–106283.
8.
Yurkiewicz, Ilana R., et al.. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology. 7(5). 579–583.
9.
Altrichter, Sabine, Tomasz Hawro, Michaela Liedtke, et al.. (2018). In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional. Allergy. 73(7). 1497–1504.
10.
Berdeja, Jesús G., Yi Lin, Noopur Raje, et al.. (2017). Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. Blood. 130(Suppl_1). 740–740.
11.
Kaufman, Gregory P., Stanley L. Schrier, Richard Lafayette, et al.. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 130(7). 900–902.
12.
Hansmann, Leo, Arnold Han, Livius Penter, Michaela Liedtke, & Mark M. Davis. (2017). Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. Cancer Immunology Research. 5(9). 744–754.
13.
Advani, Anjali S., Elias Jabbour, Matthias Stelljes, et al.. (2017). Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status. Blood. 130. 2557–2557.
14.
Kantarjian, Hagop M., Daniel J. DeAngelo, Matthias Stelljes, et al.. (2017). Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study. Blood. 130. 2574–2574.
15.
Gertz, Morie A., Heather Landau, Raymond L. Comenzo, et al.. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology. 34(10). 1097–1103.
16.
Cohen, Adam D., Heather Landau, Emma C. Scott, et al.. (2016). Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood. 128(22). 645–645.
17.
Hansmann, Leo, Lisa K. Blum, Chia‐Hsin Ju, et al.. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. Cancer Immunology Research. 3(6). 650–660.
18.
Iwasaki, Masayuki, Michaela Liedtke, Andrew J. Gentles, & Michael L. Cleary. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell stem cell. 17(4). 412–421.
19.
Connelly, Stephen, Yu Wang, Lei Zhao, et al.. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences. 110(24). 9992–9997.
20.
Liedtke, Michaela, Paul A. Hamlin, Craig H. Moskowitz, & Andrew D. Zelenetz. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Annals of Oncology. 17(6). 909–913.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lia Gore Breakdown of academic impact, for papers by Josef Vormoor Breakdown of academic impact, for papers by Keith Stockerl‐Goldstein Breakdown of academic impact, for papers by Pamela S. Becker Breakdown of academic impact, for papers by David A. Rizzieri Breakdown of academic impact, for papers by Benjamin Esterni Breakdown of academic impact, for papers by Albrecht Reichle Breakdown of academic impact, for papers by Tibor Kovacsovics Breakdown of academic impact, for papers by Hetty E. Carraway Breakdown of academic impact, for papers by Muzaffar H. Qazilbash